Pharmacogenomics and pharmacoproteomics in the evaluation and management of short stature

Rosenfeld, Ron G.

doi:10.1530/eje-07-0186

Cited by 18 publications

(15 citation statements)

References 29 publications

(18 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It will require a large-scale, prospective, wellcontrolled study, with appropriate assessment of proteomic and genomic markers of GH action, as well as auxological data, to settle this issue. Nevertheless, this study served to open the door to the potential importance of genomic and proteomic biomarkers as indicators and predictors of GH responsiveness [39]. Another study, conducted by Jorge and colleagues, is a good example of a direct relation between genetic variability and adult height after long-term treatment with hGH, since there are only few data in literature about long-term effects of drugs.…”

Section: Growth Hormone Deficiencymentioning

confidence: 95%

Pediatric pharmacogenetic and pharmacogenomic studies: the current state and future perspectives

Russo

Capasso

Paolucci

et al. 2010

Eur J Clin Pharmacol

View full text Add to dashboard Cite

Genetic differences between individuals can explain some of the variability observed during drug treatment. Many studies have correlated the different pharmacological response to genetic variability, but most of them have been conducted on adult populations. Much less attention has been given to pediatric population. Pediatric patients constitute a vulnerable group with regard to rational drug prescribing since they present differences arising from the various stage of development. However, only few steps have been made in developmental pharmacogenomics. This review attempts to describe the current methods for pharmacogenetic and pharmacogenomic studies, providing some of the most studied examples in pediatric patients. It also gives an overview on the implication and importance of microRNA polymorphisms, transcriptomics, metabonomics and proteomics in pharmacogenetics and pharmacogenomics studies.

show abstract

Section: Growth Hormone Deficiencymentioning

confidence: 95%

Pediatric pharmacogenetic and pharmacogenomic studies: the current state and future perspectives

Russo

Capasso

Paolucci

et al. 2010

Eur J Clin Pharmacol

View full text Add to dashboard Cite

show abstract

“…A main focus has been exploring the technology to study complex multigenetic disease, to predict drug response, to individualize treatment and to discriminate between healthy and diseased individual [22][23][24]. We also had strongly interested in the proteomics approach for the toxicological-and pharmacological evaluation.…”

Section: Application Of Proteomics To Pk-pd Modeling and Simulationmentioning

confidence: 99%

The Application of Proteomics to PK-PD Modeling and Simulation

Sako¹,

Haniu²,

Hasegawa³

2011

JBB

View full text Add to dashboard Cite

Pharmacokinetic-pharmacodynamic (PK-PD) modeling and simulation can be an invaluable tool for use in making crucial decisions in drug development and clinical settings, including those pertaining to compound selection, dose selection, study design, and patient population, all of which can impact the cost of development and treatment. Clinical PK-PD modeling and simulation of antimicrobial agents are possible because minimum inhibitory concentration (MIC) values can be easily measured in the hospital laboratory. However, no such easily measured clinical markers are available for many other types of drugs. In this point of view, we thought that the proteomics approach may be available for find the direct PD parameter such as drug specific biomarker. Many reports also suggest that proteomics is a promising tool in the search for drug-specific biomarker proteins that could be used in PK-PD modeling and simulation. Thus, by enabling examination of drug-induced changes in the expression of specific biomarker proteins, proteomic data could be used in PD analyses in much the same way that MICs are used in PD evaluations of antimicrobial agents.

show abstract

“…Quando um dos pais é baixo, deve-se admitir a possibilidade da presença de doença hereditária de caráter dominante. É possível que, no futuro, a disponibilidade de estudos moleculares possa permitir o reconhecimento de alterações gênicas que isoladamente ou em conjunto determinem a perda estatural (7). Com isso, pacientes que hoje são classificados como portadores de BEI passarão a ter o diagnóstico etiológico conhecido.…”

Section: Retardo Constitucional Do Crescimento E Puberdade (Rccp)unclassified

Uso de GH em pacientes com baixa estatura idiopática

Longui

2008

Arq Bras Endocrinol Metab

View full text Add to dashboard Cite

RESUMOPacientes com baixa estatura idiopática podem ser tratados com gH. os critérios clínicos e laboratoriais utilizados na decisão do uso do gH, bem como no reconhecimento da responsividade dos indivíduos ao tratamento, são discutidos. não apenas os resultados antropométricos, mas também os aspectos éticos e psicossociais devem ser considerados na avaliação dos custos/ benefícios envolvidos no tratamento com gH em pacientes com baixa estatura idiopática. Keywords: idiopathic short stature; short stature therapy; growth hormone; Familial short stature; constitutional delay of growth and puberty O tratamento da baixa estatura (BE) com hormônio de crescimento humano (GH) tem sido utilizado há várias décadas. Inicialmente em pacientes com deficiência de GH e, logo a seguir, em doenças genéticas, como a síndrome de Turner, e em doenças crônicas, como a insuficiência renal. Nesta mesma época, indivíduos com estatura abaixo do normal para a idade e o sexo, ou abaixo do esperado para o padrão familial (estatura-alvo familial ou target height, TH) também passaram a ser tratados com GH (1). Hoje, a experiência clínica obtida com o tratamento de centenas de milhares de pacientes com BE permite avaliar os riscos e os benefícios envolvidos no uso de GH, bem como reconhecer os principais fatores determinantes da resposta terapêutica (2).Um número significante de pacientes tratados com GH corresponde a crianças e adolescentes com baixa estatura idiopática (BEI). Trata-se de grupo heterogêneo, que inclui três subclasses de diagnóstico: a baixa estatura familial (BEF), o retardo constitucional do crescimento e puberdade (RCCP) e a BEI propriamente dita (3). Na prática, uma parcela substancial de casos apresenta elementos comuns a mais de uma subclasse diagnóstica. Isso se deve ao

show abstract

Pharmacogenomics and pharmacoproteomics in the evaluation and management of short stature

Cited by 18 publications

References 29 publications

Pediatric pharmacogenetic and pharmacogenomic studies: the current state and future perspectives

Pediatric pharmacogenetic and pharmacogenomic studies: the current state and future perspectives

The Application of Proteomics to PK-PD Modeling and Simulation

Uso de GH em pacientes com baixa estatura idiopática

Contact Info

Product

Resources

About